Methylation analysis shows that in breast cancer [99,100,101,102] and colorectal cancer [103,104,105], the hypermethylated promoter of GSDME was relevant to patients’ prognosis, suggesting that GSDME methylation could be a potential detection and prognostic marker [99,105]. Here, GSDME is linked to breast cancer.